Regeneron Revenue Jumps 36% as Key Drugs Post Gains
The company reported higher quarterly revenue and earnings, expanded its Sanofi alliance, and raised parts of its 2026 financial outlook.
Makkler Newsroom · Oct 30, 09:10 PM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $989.00 (+3.5%)
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.